Lonza buys Belgian CRO Algonomics
This article was originally published in Scrip
Just days after calling off its planned acquisition of Patheon, reducing earnings guidance and announcing cost-cutting plans, Lonza has acquired the Belgian biotech contract research organisation, Algonomics. The price paid was not disclosed. Algonomics strengthens Lonza in protein design technology.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.